Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-321 in Adult FSHD Patients
NCT06907875Phase 2Active, not recruiting
- Sponsor
- Epicrispr Biotechnologies
- Start
- May 2025
- Primary completion
- Jul 2027
- Countries
- 3
01
Overview
A Phase 2 trial of EPI-321 in facioscapulohumeral muscular dystrophy (FSHD), sponsored by Epicrispr Biotechnologies. Started May 2025; status: active, not recruiting.
02
Drugs
EPI-321
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT06907875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06907875.